Panzilan (Pantoprazole)

Pantoprazole blocks the H+/K+‑ATPase enzyme, commonly called the gastric proton pump, on the surface of parietal cells. By inhibiting this final step of acid secretion, it raises gastric pH and decreases the amount of acid released into the stomach, providing lasting acid control.

The specific dose of Panzilan is determined by the prescribing clinician based on the individual’s diagnosis, severity of disease and response to therapy. Healthcare professionals set the appropriate strength, frequency and duration according to current clinical guidelines.

Pantoprazole is classified as pregnancy category B in the EU, indicating that animal studies have not shown risk but there are limited human data. It should be used only if the potential benefit justifies any possible risk to the fetus. Pantoprazole passes into breast milk in small amounts; breastfeeding mothers should consult their physician before use.

To request Panzilan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Pantoprazole, the active ingredient in Panzilan, shares the core mechanism of acid suppression with other PPIs such as omeprazole and esomeprazole. Differences lie in pharmacokinetic profiles, drug‑interaction potential and metabolic pathways; pantoprazole has a lower propensity for CYP‑mediated interactions, which can be advantageous for patients on multiple medications.

Panzilan tablets should be stored at ambient temperature, below 25 °C, in the original packaging. Protect the product from moisture, heat and direct sunlight to maintain potency throughout its shelf life.

Panzilan is supplied as oral tablets that are swallowed whole with water. It can be taken with or without food, although taking it before a meal may improve acid‑control onset. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events linked to pantoprazole include severe allergic reactions, Clostridioides difficile‑associated colitis, acute interstitial nephritis, prolonged low magnesium levels, and increased risk of bone fractures with long‑term use. Any unexpected symptoms should be reported to a medical professional promptly.

Pantoprazole is contraindicated in patients with known hypersensitivity to pantoprazole or other proton pump inhibitors. Caution is also advised for individuals with severe liver impairment, those taking contraindicated medications such as certain antifungals, and patients with a history of unexplained hypomagnesemia.